The role of thiamine in HIV infection

International Journal of Infectious Diseases

Volumn 17, Issue 4, 2013, Pages

  Lu'o'ng, Khanh vinh quốc ^a   Ngyễn, Lan Thi Hoàng ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

HIV; Human immunodeficiency virus; Thiamine; Transketolase; Vitamin B1

Indexed keywords

CASPASE; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE A; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; HEME OXYGENASE 1; HEME OXYGENASE 2; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROSTAGLANDIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; THIAMINE;

AIDS PATIENT; ALDOSTERONE URINE LEVEL; ANGIOGENESIS; CELL ACTIVATION; CELL DEATH; CELL KILLING; CELL MEMBRANE; CELL STRAIN HEPG2; DISEASE COURSE; DNA FRAGMENTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PERITONEAL FIBROSIS; PNEUMOCYSTIS PNEUMONIA; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; THIAMINE DEFICIENCY; TISSUE INJURY;

HIV INFECTIONS; HUMANS; THIAMINE; THIAMINE DEFICIENCY;

EID: 84875364682     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.11.019     Document Type: Review

References (136)

1. Tang A.M., Graham N.M., Kirby A.J., McCall L.D., Willett W.C., Saah A.J. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men. Am J Epidemiol 1993, 138:937-951.
2. Abrams B., Duncan D., Hertz-Picciotto I. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. J Acquir Immune Defic Syndr 1993, 6:949-958.
3. Villamor E., Msamanga G., Spiegelman D., Antelman G., Peterson K.E., Hunter D.J., Fawzi W.W. Effect of multivitamin and vitamin A supplements on weight gain during pregnancy among HIV-1-infected women. Am J Clin Nutr 2002, 76:1082-1090.
4. Merchant A.T., Msamanga G., Villamor E., Saathoff E., O'brien M., Hertzmark E., et al. Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension. J Nutr 2005, 135:1776-1781.
5. Villamor E., Saathoff E., Bosch R.J., Hertzmark E., Baylin A., Manji K., et al. Vitamin supplementation of HIV-infected women improves postnatal child growth. Am J Clin Nutr 2005, 81:880-888.
6. Kawai K., Kupka R., Mugusi F., Aboud S., Okuma J., Villamor E., et al. A randomized trial to determine the optimal dosage of multivitamin supplements to reduce adverse pregnancy outcomes among HIV-infected women in Tanzania. Am J Clin Nutr 2010, 91:391-397.
7. Tang A.M., Graham N.M.H., Saah A.J. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am J Epidemiol 1998, 143:1244-1256.
8. Tattevin P., Souala F., Revest M., Michelet C., Taussig D. Confusion, memory disorders, and ophthalmoparesis in a patient with AIDS. Lancet 2006, 367:368.
9. Cissé A.F., Camara N., Diallo L.L., Morel Y., Koné S., Camara M.I., et al. [Gayet-Wernicke's encephalopathy. A study of 13 cases observed in a refugee population hospitalized at the Conakry Teaching Hospital] (in French). Bull Soc Pathol Exot 2008, 101:402-403.
10. Cognat E., Hainque E., Mesnage V., Levy R. [Severe dysautonomia revealing Wernicke's encephalopathy] (in French). Rev Neurol (Paris) 2011, 167:250-253.
11. Mouly S., Khuong M.A., Cabie A., Saimot A.G., Coulad J.P. Beri-Beri and thiamine deficiency in HIV infection. AIDS 1996, 10:931-932.
12. Butterworth R.F., Gaudreau C., Vincelette J., Bourgault A.M., Lamothe F., Nutini A.M. Thiamine deficiency and Wernicke's encephalopathy in AIDS. Metab Brain Dis 1991, 6:207-212.
13. Müri R.M., Von Overbeck J., Furrer J., Ballmer P.E. Thiamin deficiency in HIV-positive patients: evaluation by erythrocyte transketolase activity and thiamin pyrophosphate effect. Clin Nutr 1999, 18:375-378.
14. Shanina E., Gelman B., Smith R.G. Thiamine deficiency in HIV associated NRTI neuropathy. Ann Neurol 2008, 64:S62.
15. Schramm C., Wanitschke R., Galle P.R. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol 1999, 16:733-735.
16. Arici C., Tebaldi A., Quinzan G.P., Maggiolo F., Ripamonti D., Suter F. Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. Int J STD AIDS 2001, 12:407-409.
17. Koch H.J. [Fatty liver and serum lactate elevation in an HIV patient-is the routine determination of thiamine and riboflavin during HAART useful?] (in German). Dtsch Med Wochenschr 2003, 128:1134.
18. Bowers J.M., Bert-Moreno A. Treatment of HAART-induced lactic acidosis with B vitamin supplements. Nutr Clin Pract 2004, 19:375-378.
19. Pedrol E., Ribell M., Deig E., VillàMdel C., Miró O., Garrabou G., Soler A. [Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors] (in Spanish). Med Clin (Barc) 2005, 125:201-204.
20. 2 stress response promotes increased survival for Schizosaccharomyces pombe cells expressing HIV-1 Vpr. Folia Microbiol (Praha) 2006, 51:406-412.
21. Nishiura Y., Nakamura T., Fukushima N., Nakamura H., Ida H., Aramaki T., Eguchi K. Disulfide-mediated apoptosis of human T-lymphotropic virus type I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther 2009, 14:533-542.
22. Shoji S., Furuishi K., Ogata A., Yamataka K., Tachibana K., Mukai R., et al. An allosteric drug, o,o'-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B. Biochem Biophys Res Commun 1998, 249:745-753.
23. Shoji S., Furuishi K., Misumi S., Miyazaki T., Kino M., Yamataka K. Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type 1) production. Biochem Biophys Res Commun 1994, 205:967-975.
24. Johnston C.I. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994, 23:258-268.
25. Oullette D.R., Kelly J.W., Anders G.T. Serum angiotensin-converting enzyme level is elevated in patients with human immunodeficiency virus infection. Arch Intern Med 1992, 152:321-324.
26. Singer F., Talavera W., Zumoff B. Elevated levels of angiotensin-converting enzyme in Pneumocystis carinii pneumonia. Chest 1989, 95:803-806.
27. Bird J.E., Durham S.K., Giancarli M.R., Gitlitz P.H., Pandya D.G., Dambach D.M., et al. Captopril prevents nephropathy in HIV-transgenic mice. J Am Soc Nephrol 1998, 9:1441-1447.
28. Kimmel P.L., Mishkin G.J., Umana W.O. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 1996, 28:202-208.
29. Wei A., Burns G.C., Williams B.A., Mohammed N.B., Visintainer P., Sivak S.L. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 2003, 64:1462-1471.
30. Auroj K., Pathmanand C., Sueblinvong V., Thisyakom C., Chotivitayatarakom P. Ventricular functions in children with human immunodeficiency virus infection after ACE inhibitors. Southeast Asian J Trop Med Public Health 1997, 28:375-379.
31. Margolin A., Avants S.K., Setaro J.F., Rinder H.M., Grupp L., Cocaine H.I.V. and their cardiovascular effects: is there a role for ACE inhibitor therapy?. Drug Alcohol Depend 2000, 61:35-45.
32. Kozlowski S., Corr M., Takeshita T., Boyd L.F., Pendleton C.D., Germain R.N., et al. Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med 1992, 175:1417-1422.
33. Hastings M.M., Van J.L. Sodium deprivation during thiamin deficiency in rats: hormonal, histological, and behavioral responses. J Nutr 1981, 111:1955-1963.
34. Tanaka T., Sohmiya K., Kono T., Terasaki F., Horie R., Ohkaru Y., et al. Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency. Mol Cell Biochem 2007, 299:23-35.
35. Furlini G., Re M.C., La Placa M. Increased poly(ADP-ribose)polymerase activity in cells infected by human immunodeficiency virus type 1. Microbiologica 1991, 14:141-148.
36. Wiley C.A., Achim C.L., Hammond R., Love S., Masliah E., Radhakrishnan L., et al. Damage and repair of DNA in HIV encephalitis. J Neuropathol Exp Neurol 2000, 59:955-965.
37. Ha H.C., Juluri K., Zhou Y., Leung S., Hermankova M., Snyder S.H. Poly(ADP-ribose) polymerase 1 is required for efficient HIV-1 integration. PNAS 2001, 98:3364-3368.
38. Kameoka M., Nukuzuma S., Itaya A., Tanaka Y., Ota K., Inada Y., et al. Poly(ADP-ribose) polymerase 1 is required for integration of the human immunodeficiency virus type 1 genome near centromeric alphoid DNA in human and murine cells. Biochem Biophys Res Commun 2005, 334:412-417.
39. Kameoka M., Nukuzuma S., Itaya A., Tanaka Y., Ota K., Ikuta K., Yoshihara K. RNA interference directed against poly(ADP-ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol 2004, 78:8931-8934.
40. Shin B.H., Choi S.H., Cho E.Y., Shin M.J., Hwang K.C., Cho H.K., et al. Thiamine attenuates hypoxia-induced cell death in cultured neonatal rat cardiomyocytes. Mol Cells 2004, 18:133-140.
41. Yadav U.C., Kalariya N.M., Srivastava S.K., Ramana K.V. Protective role of benfotiamine, a fat soluble vitamin B1 analogue, in the lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic Biol Med 2010, 48:1423-1434.
42. Frédérich M., Delvaux D., Gigliobianco T., Gangolf M., Dive G., Mazzucchelli G., et al. Thiaminylated adenine nucleotides. FEBS J 2009, 276:3256-3268.
43. Tanaka T., Yamamoto D., Sato T., Tanaka S., Usui K., Manabe M., et al. Adenosine thiamine triphosphate (AThTP) inhibits poly(ADP-ribose) polymerase 1 (PARP-1) activity. J Nutr Sci Vitaminol 2011, 57:192-196.
44. Wang L., Mukherjee S., Jia F., Narayan O., Zhao L.J. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 1995, 270:25564-25569.
45. Perkins N.D., Edwards N.L., Duckett C.S., Agranoff A.B., Schmid R.M., Nabel G.J. A cooperative interaction between NF-κB and Sp1 is required for HIV-1 enhancer activation. EMBO J 1993, 12:3551-3558.
46. Muckenfuss H., Kaiser J.K., Krebil E., Battenberg M., Schwer C., Cichutek K., et al. Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucleic Acids Res 2007, 35:3784-3796.
47. Guo X., Roldan A., Hu J., Wainberg M.A., Liang C. Mutation of the Sp1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J Virol 2005, 79:1803-1812.
48. Nabokina S.M., Said H.M. Characterization of the 5'-regulatory region of the human thiamin transporter SLC19A3: in vitro and in vivo studies. Am J Physiol Gastrointest Liver Physiol 2004, 287:G822-G829.
49. Nabokina S.M., Reidling J.C., Said H.M. Differentiation-dependent up-regulation of intestinal thiamin uptake: cellular and molecular mechanisms. J Biol Chem 2005, 280:32676-32682.
50. Thakur B.K., Chandra A., Dittrich T., Welte K., Chandra P. Inhibition of SIRT1 by HIV-1 viral protein Tat results in activation of p53 pathway. Biochem Biophys Res Commun 2012, 424:245-250.
51. Yan H., Liu N., Zhao Z., Zhang X., Xu H., Shao B., Yan W. Expression and purification of human TAT-p53 fusion protein in Pichia pastoris and its influence on HepG2 cell apoptosis. Biotechnol Lett 2012, 34:1217-1223.
52. Imbeault M., Ouellet M., Tremblay M.J. Microarray study reveals that HIV-1 induces rapid type-I interferon-dependent p53 mRNA up-regulation in human primary CD4+ T cells. Retrovirology 2009, 6:5.
53. Mukerjee R., Deshmane S.L., Fan S., Del Valle L., White M.K., Khalili K., et al. Involvement of the p53 and p73 transcription factors in neuroAIDS. Cell Cycle 2008, 7:2682-2690.
54. Jayadev S., Yun B., Nguyen H., Yokoo H., Morrison R.S., Garden G.A. The glial response to CNS HIV infection includes p53 activation and increased expression of p53 target genes. J Neuroimmune Pharmacol 2007, 2:359-370.
55. Jones G.J., Barsby N.L., Cohen E.A., Holden J., Harris K., Dickie P., Jhamandas J., Power C. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 2007, 27:3703-3711.
56. Lo P.K., Chen J.Y., Tang P.P., Lin J., Lin C.H., Su L.T., et al. Identification of a mouse thiamine transporter gene as a direct transcriptional target for p53. J Biol Chem 2001, 276:37186-37193.
57. + modulates p53 DNA binding specificity and function. Mol Cell Biol 2004, 24:9958-9967.
58. Yang Z., Ge J., Yin W., Shen H., Liu H., Guo Y. [The expression of p53, MDM2 and Ref1 gene in cultured retina neurons of SD rats treated with vitamin B1 and/or elevated pressure] (in Chinese). Yan Ke Xue Bao 2004, 20:259-263.
59. Salvesen G.S., Riedl S.J. Caspase mechanisms. Adv Exp Med Biol 2008, 615:13-23.
60. James H.J., Sharer L.R., Zhang Q., Wang H.G., Epstein L.G., Reed J.C., Gelbard H.A. Expression of caspase 3 in brains from paediatric patients with HIV-1 encephalitis. Neuropathol Appl Neurobiol 1999, 25:380-386.
61. Ullrich C.K., Groopman J.E., Ganju R.K. HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood 2000, 96:1438-1442.
62. Cicala C., Arthos J., Rubbert A., Selig S., Wildt K., Cohen O.J., Fauci A.S. HIV-1 envelope induces activation of caspase 3 and cleavage of focal adhesion kinase in primary human CD4+ T cells. Proc Natl Acad Sci U S A 2000, 97:1178-1183.
63. Garg H., Blumenthal R. HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol 2006, 79:351-362.
64. Bellet V., Duval R., Delebassée S., Cook-Moreau J., Bosgiraud C. AZT inhibits visna/maedi virus-induced apoptosis. Arch Virol 2004, 149:583-601.
65. Liu S., Huang H., Lu X., Golinski M., Comesse S., Watt D., et al. Down-regulation of thiamine transporter THTR2 gene expression in breast cancer and its association with resistance to apoptosis. Mol Cancer Res 2003, 1:665-673.
66. Chornyy S., Parkhomenko J., Chorna N. Thiamine deficiency caused by thiamine antagonists triggers upregulation of apoptosis inducing factor gene expression and leads to caspase 3-mediated apoptosis in neuronally differentiated rat PC-12 cells. Acta Biochim Pol 2007, 54:315-322.
67. Gadau S., Emanueli C., Van Linthout S., Graiani G., Todaro M., Meloni M., et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006, 49:405-420.
68. Kang K.D., Majid A.S., Kim K.A., Kang K., Ahn H.R., Nho C.W., Jung S.H. Sulbutiamine counteracts trophic factor deprivation induced apoptotic cell death in transformed retinal ganglion cells. Neurochem Res 2010, 35:1828-1839.
69. Maggirwar S.B., Tong N., Ramirez S., Gelbard H.A., Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase 3beta contributes to Tat-mediated neurotoxicity. J Neurochem 1999, 73:578-586.
70. Sui Z., Sniderhan L.F., Fan S., Kazmierczak K., Reisinger E., Kovács A.D., et al. Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase 3beta to antagonize nuclear factor-kappaB survival pathway in neurons. Eur J Neurosci 2006, 23:2623-2634.
71. Nguyen T.B., Lucero G.R., Chana G., Hult B.J., Tatro E.T., Masliah E., et al. Glycogen synthase kinase 3beta (GSK-3beta) inhibitors AR-A014418 and B6B3O prevent human immunodeficiency virus-mediated neurotoxicity in primary human neurons. J Neurovirol 2009, 15:434-438.
72. Zhao J., Sun X., Yu Z., Pan X., Gu F., Chen J., et al. Exposure to pyrimidine increases beta-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthetase kinase 3 activity in the brain. Neurotox Res 2010, 19:575-583.
73. Pan X., Gong N., Zhao J., Yu Z., Gu F., Chen J., et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010, 133:1342-1351.
74. Mellanen L., Ingman T., Lähdevirta J., Lauhio A., Ainamo A., Konttinen Y.T., et al. Matrix metalloproteinases-1, -3, and -8 and myeloperoxidase in saliva of patients with human immunodeficiency virus infection. Oral Dis 1996, 2:263-271.
75. Mellanen L., Lähdevirta J., Tervahartiala T., Meurman J.H., Sorsa T. Matrix metalloproteinases-7, -8, -9, -25, and -26 and CD43, -45, and -68 cell-markers in HIV-infected patients' saliva and gingival tissue. J Oral Pathol Med 2006, 35:530-539.
76. Naesse E.P., Schreurs O., Helgeland K., Steinsvoll S. Matrix metalloproteinases and their inhibitors in gingival mast cells in persons with and without human immunodeficiency virus infection. J Peridontal Res 2003, 38:575-582.
77. Ahuja T.S., Gopalani A., Davies P., Ahuja H. Matrix metalloproteinase 9 expression in renal biopsies of patients with HIV-associated nephropathy. Nephron Clin Pract 2003, 95:c100-c104.
78. Jörg A., Grubert T., Grimm T., Guenzi E., Naschberger E., Samson E., et al. Maternal HIV type 1 infection suppresses MMP-1 expression in endothelial cells of uninfected newborns: nonviral vertical transmission of HIV type 1-related effects. AIDS Res Hum Retroviruses 2005, 21:940-944.
79. Ragin A.B., Wu Y., Ochs R., Scheidegger R., Cohen B.A., McArthur J.C., et al. Serum matrix metalloproteinase levels correlate with brain injury in human immunodeficiency virus infection. J Neurovirol 2009, 15:275-281.
80. Conant K., McArthur J.C., Griffin D.E., Sjulson L., Wahl L.M., Irani D.N. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 1999, 46:391-398.
81. Louboutin J.P., Reyes B.A., Agrawal L., Van Bockstaele E.J., Strayer D.S. HIV-1 gp120 upregulates matrix metalloproteinases and their inhibitors in a rat model of HIV encephalopathy. Eur J Neurosci 2011, 34:2015-2023.
82. Toschi E., Barillari G., Sgadari C., Bacigalupo I., Cereseto A., Carlei D., et al. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 2001, 12:2934-2946.
83. Latronico T., Liuzzi G.M., Riccio P., Lichtner M., Mengoni F., D'Agostino C., et al. Antiretroviral therapy inhibits matrix metalloproteinase 9 from blood mononuclear cells of HIV-infected patients. AIDS 2007, 21:677-684.
84. Liuzzi G.M., Mastroianni C.M., Latronico T., Mengoni F., Fasano A., Lichtner M., et al. Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 2004, 127:398-407.
85. Calingasan N.Y., Gibson G.E. Dietary restriction attenuates the neuronal loss, induction of heme oxygenase-1 and blood-brain barrier breakdown induced by impaired oxidative metabolism. Brain Res 2000, 885:62-69.
86. Beauchesne é., Desjardins P., Hazell A.S., Butterworth R.F. eNOS gene deletion restores blood-brain barrier integrity and attenuates neurodegeneration in the thiamine-deficient mouse brain. J Neurochem 2009, 111:452-459.
87. Kohda Y., Shirakawa H., Yamane K., Otsuka K., Kono T., Terasaki F., Tanaka T. Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. J Toxicol Sci 2008, 33:459-472.
88. Tarallo S., Beltramo E., Berrone E., Dentelli P., Porta M. Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetol 2010, 47:105-111.
89. Kobayashi T., Notoya K., Nakamura A., Akimoto K. Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis. Inflamm Res 2005, 54:249-255.
90. Albini A., Benelli R., Presta M., Rusnati M., Ziche M., Rubartelli A., et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996, 12:289-297.
91. Albini A., Soldi R., Giunciuglio D., Giraudo E., Benelli R., Primo L., et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996, 2:1371-1375.
92. Nyagol J., De Falco G., Lazzi S., Luzzi A., Cerino G., Shaheen S., et al. HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. J Hematop 2008, 1:3-10.
93. Masood R., Cai J., Zheng T., Smith D.L., Naidu Y., Gill P.S. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A 1997, 94:979-984.
94. Mercié P., Devianne I., Viallard J.F., Faure I., Pellegrin I., Leng B., et al. Vascular endothelial growth factor (VEGF165) plasma level increase with immunodepression in AIDS patients with Kaposi's sarcoma. Microvasc Res 1999, 57:208-210.
95. Samaniego F., Young D., Grimes C., Prospero V., Christofidou-Solomidou M., DeLisser H.M., et al. Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts. Cell Growth Differ 2002, 13:387-395.
96. Sporer B., Koedel U., Paul R., Eberle J., Arendt G., Pfister H.W. Vascular endothelial growth factor (VEGF) is increased in serum, but not in cerebrospinal fluid in HIV associated CNS diseases. J Neurol Neurosurg Psychiatry 2004, 75:298-300.
97. Nakamura S., Murakami-Mori K., Rao N., Weich H.A., Rajeev B. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. J Immunol 1997, 158:4992-5001.
98. Mitola S., Sozzani S., Luini W., Primo L., Borsatti A., Weich H., Bussolino F. Tat-human immunodeficiency virus 1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor 1. Blood 1997, 90:1365-1372.
99. Korgaonkar S.N., Feng X., Ross M.D., Lu T.C., D'Agati V., Iyengar R., et al. HIV-1 upregulates VEGF in podocytes. J Am Soc Nephrol 2008, 19:877-883.
100. Pore N., Gupta A.K., Cerniglia G.J., Maity A. HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 2006, 8:889-895.
101. Nakagawa H., Yoneda M., Maeda A., Umehara F., Kuriyama M. [Thiamine deficiency polyneuropathy after gastrectomy associated with high level of serum vascular endothelial growth factor (VEGF). A case report] (in Japanese). Rinsho Shinkeigaku 2004, 44:91-95.
102. Imai N., Kubota M., Saitou M., Yagi N., Serizawa M., Kobari M. Increase of serum vascular endothelial growth factors in wet beriberi: two case reports. Intern Med 2012, 51:929-932.
103. Kihm L.P., Müller-Krebs S., Klein J., Ehrlich G., Mertes L., Gross M.L., et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 2011, 22:914-926.
104. Katare R., Caporali A., Emanueli C., Madeddu P. Benfotiamine improves functional recovery of the infarcted heart via activation of pro-survival G6PD/Akt signaling pathway and modulation of neurohormonal response. J Mol Cell Cardiol 2010, 49:625-638.
105. Seu L., Burt T.D., Witte J.S., Martin J.N., Deeks S.G., McCune J.M. Variations in the heme oxygenase-1 microsatellite polymorphism are associated with plasma CD14 and viral load in HIV-infected African-Americans. Genes Immun 2012, 13:258-267.
106. Mühl H., Paulukat J., Höfler S., Hellmuth M., Frazen R., Pfeilschifter J. The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase 1 in DLD-1 colon carcinoma cells. Br J Pharmacol 2004, 143:890-898.
107. Devadas K., Dhawan S. Hemin activation ameliorates HIV-1 infection via heme oxygenase 1 induction. J Immunol 2006, 176:4252-4257.
108. Shankaran P., Vlkova L., Liskova J., Melkova Z. Heme arginate potentiates latent HIV-1 reactivation while inhibiting the acute infection. Antiviral Res 2011, 92:434-446.
109. Ke Z.J., DeGiorgio L.A., Volpe B.T., Gibson G.E. Reversal of thiamine deficiency-induced neurodegeneration. J Neuropathol Exp Neurol 2003, 62:195-207.
110. Basselin M., Ramadan E., Igarashi M., Chang L., Chen M., Kraft A.D., et al. Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats. J Cereb Blood Flow Metab 2011, 31:486-493.
111. Pereira C.F., Boven L.A., Middel J., Verhoef J., Nottet H.S. Induction of cyclooxygenase 2 expression during HIV-1-infected monocyte-derived macrophage and human brain microvascular endothelial cell interactions. J Leukoc Biol 2000, 68:423-428.
112. Blanco A., Alvarez S., Fresno M., Muñoz-Fernández M.A. Extracellular HIV-Tat induces cyclooxygenase 2 in glial cells through activation of nuclear factor of activated T cells. J Immunol 2008, 180:530-540.
113. Pu H., Hayashi K., Andras I.E., Eum S.Y., Hennig B., Toborek M. Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood brain barrier. Brain Res 2007, 1184:333-344.
114. Bagetta G., Corasaniti M.T., Paoletti A.M., Berliocchi L., Nisticò R., Giammarioli A.M., et al. HIV-1 gp120-induced apoptosis in the rat neocortex involves enhanced expression of cyclo-oxygenase type 2 (COX-2). Biochem Biophys Res Commun 1998, 244:819-824.
115. Rahmouni S., Aandahl E.M., Nayjib B., Zeddou M., Giannini S., Verlaet M., et al. Cyclo-oxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T-cell dysfunction in mice. Biochem J 2004, 384:469-476.
116. Gu B., Desjardins P., Butterworth R.F. Selective increase of neuronal cyclooxygenase 2 (COX-2) expression in vulnerable brain regions of rats with experimental Wernicke's encephalopathy: effect of numesulide. Metab Brain Dis 2008, 23:175-187.
117. Liu S., Stromberg A., Tai H.H., Moscow J.A. Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. Mol Cancer Res 2004, 2:477-487.
118. Tai H.H., Tong M., Ding Y. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat 2007, 83:203-208.
119. Yaday U.C., Subramanyam S., Ramana K.V. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci 2009, 50:2276-2282.
120. Pitrak D.L., Bak P.M., DeMarais P., Novak R.M., Andersen B.R. Depressed neutrophil superoxide production in human immunodeficiency virus infection. J Infect Dis 1993, 167:1406-1410.
121. Repetto M., Reides C., Gomez Carretero M.L., Costa M., Griemberg G., Llesuy S. Oxidative stress in blood of HIV infected patients. Clin Chim Acta 1996, 255:107-117.
122. Sappey C., Legrand-Poels S., Best-Belpomme M., Favier A., Rentier B., Piette J. Stimulation of glutathione peroxide activity decreases HIV type 1 activation after oxidative stress. AIDS Res Hum Retroviruses 1994, 10:1451-1461.
123. Allard J.P., Aghdassi E., Chau J., Salit I., Walmsley S. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. Am J Clin Nutr 1998, 67:143-147.
124. Kline E.R., Kleinhenz D.J., Liang B., Dikalov S., Guidot D.M., Hart C.M., et al. Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration. Am J Physiol Heart Circ Physiol 2008, 294:H2792-H2804.
125. Calingasan N.Y., Chun W.J., Park L.C., Gibson G.E. Oxidative stress is associated with region-specific neuronal death during thiamine deficiency. J Neuropathol Exp Neurol 1999, 58:946-958.
126. Gioda C.R., de Oliveira Barreto T., Prímola-Gomes T.N., de Lima D.C., Campos P.P., Capettini Ldos S., et al. Cardiac oxidative stress is involved in heart failure induced by thiamine deprivation in rats. Am J Physiol Heart Circ Physiol 2010, 298:H2039-H2045.
127. Lukienko P.I., Mel'nichenko N.G., Zverinskii I.V., Zabrodskaya S.V. Antioxidant properties of thiamine. Bull Exp Biol Med 2000, 130:874-876.
128. Portari G.V., Marchini J.S., Vannucchi H., Jordao A.A. Antioxidant effect of thiamine on acutely alcoholized rats and lack of efficacy using thiamine or glucose to reduce blood alcohol content. Basic Clin Pharmacol Toxicol 2008, 103:482-486.
129. Jung I.L., Kim I.G. Thiamine protects against paraquat-induced damage: scavenging activity of reactive oxygen species. Environ Toxicol Pharmacol 2003, 15:19-26.
130. Yu Q.R., Zhang Z.P., Zhang H., Lin H.T., Li X.M., Bai L., Cai W.B. Inducible nitric oxide synthase is involved in the oxidation stress induced by HIV-1 gp120 in human retina pigment epithelial cells. Chin Med J (Engl) 2008, 121:2578-2583.
131. Kuljis R.O., Shapshak P., Alcabes P., Rodríguez de la Vega P., Fujimura R., Petito C.K. Increased density of neurons containing NADPH diaphorase and nitric oxide synthase in the cerebral cortex of patients with HIV-1 infection and drug abuse. J NeuroAIDS 2002, 2:19-36.
132. Flora G., Pu H., Hennig B., Toborek M. Cyclooxygenase 2 is involved in HIV-1 Tat-induced inflammatory responses in the brain. Neuromolecular Med 2006, 8:337-352.
133. Fu W., Chai H., Yao Q., Chen C. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr 2005, 39:152-158.
134. Holguin A., O'Connor K.A., Biedenkapp J., Campisi J., Wieseler-Frank J., Milligan E.D., et al. HIV-1 gp120 stimulates proinflammatory cytokine-mediated pain facilitation via activation of nitric oxide synthase I (nNOS). Pain 2004, 110:517-530.
135. Walsh K.A., Megyesi J.F., Wilson J.X., Crukley J., Laubach V.E., Hammond R.R. Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. J Neuroinflammation 2004, 1:8.
136. Yadav U.C., Kalariya N.M., Srivastava S.K., Ramana K.V. Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic Biol Med 2010, 48:1423-1434.